Portal de investigación
Estudio intervencional de eficacia y seguridad, de fase II, aleatorizado, doble ciego, de tres grupos para investigar nirmatrelvir/ritonavir en participantes inmunocomprometidos, no hospitalizados, de al menos 12 años de edad con COVID-19 sintomático.
Datos básicos
- Código:
- C4671034
- Protocolo:
- C4671034
- EUDRACT:
- 2022-001362-35
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2023
- Año de finalización:
- 2023
Objetivos del proyecto
Objetivo Principal: Describir el efecto de nirmatrelvir/ritonavir sobre los niveles de ARN vírico en hisopos NF a lo largo del tiempo para el tratamiento de la COVID-19 en participantes inmunodeprimidos, sintomáticos, no hospitalizados, = 12 años con COVID-19. Objetivos Secundarios: - Describir el efecto de la duración del tratamiento con nirmatrelvir/ritonavir sobre la tasa de aclaramiento virológico - Describir el efecto de nirmatrelvir/ritonavir en el aclaramiento vírico - Describir la seguridad y tolerabilidad de nirmatrelvir/ritonavir - Describir el efecto de nirmatrelvir/ritonavir en la hospitalización y la mortalidad total - Evaluar nirmatrelvir/ritonavir durante la duración y gravedad de los signos y síntomas - Describir la utilización de los recursos sanitarios
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication
Gimenez, Estela; (...); Navarro, David
Article. 10.37201/req/016.2023. 2023
Accuracy and prognostic impact of FDG PET/CT and biopsyin bone marrow assessment of follicular lymphomaat diagnosis: A Nation-Wide cohort study.
Rodenas-Quinonero, Isabel; (...); Ortuno, Francisco Jose
Article. 10.1002/cam4.5424. 2022
Alternative Donor Transplantation for Severe Aplastic Anemia: A Comparative Study of the Saawp EBMT
Montoro, Juan; (...); De Latour, Regis Peffault
Meeting Abstract. 10.1182/blood-2023-174724. 2023
Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.
Chihara D; (...); Yakoub-Agha I
Letter. 10.3324/haematol.2022.281754. 2023
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN ADULT PATIENTS WITH IDH MUTATED AML AND MDS: A STUDY FROM THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR
Perez-Gonzalez, Ana; (...); Orti Pascual, Guillermo
Meeting Abstract. 2023
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Maffini, Enrico; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02027-y. 2023
Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
Berning, Philipp; (...); Glass, Bertram
Meeting Abstract. 10.1182/blood-2022-164637. 2022
Allogeneic hematopoietic stem cell transplantation achieves long-term survival in Natural killer/T-cell lymphoma in the era of Asparaginase-based Chemotherapy
Berning, P.; (...); Glass, B.
Meeting Abstract. 2023
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis.
Berning, Philipp; (...); Glass, Bertram
Article. 10.1038/s41375-023-01924-x. 2023
Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups
Rey-Bua, Beatriz; (...); Martin Garcia-Sancho, Alejandro
Article. 10.3390/cancers14225670. 2022
Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-01940-6. 2023
ANTITHYMOCYTE GLOBULIN - OR ALEMTUZUMAB-BASED GVHD PROPHYLAXIS IN REDUCED- INTENSITY CONDITIONING ALLO-HCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CR1: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY
Bug, Gesine; (...); Mohty, Mohamad
Meeting Abstract. 2023
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Autologous Stem Cell Transplantation Remains a Curative Option As Second Line Treatment for Patients with Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geth-TC/Geltamo Study
Bento, Leyre; (...); Garcia-Sancho, Alejandro Martin
Meeting Abstract. 10.1182/blood-2023-186730. 2023
Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC
Pena, Marta; (...); Balari, Anna Maria Sureda
Meeting Abstract. 10.1182/blood-2023-181815. 2023
CART-AI-Radiomics: Survival and Neurotoxicity Prediction in B-Cell Lymphoma Patients Treated with CAR-T Cells through an Imaging Features-Based Model
Ferrer Lores, Blanca; (...); Jose Terol, Maria
Meeting Abstract. 10.1182/blood-2023-185088. 2023
CNS Prophylaxis in Adult ALL Patients after Stem Cell Transplantation: An EBMT Survey on General Practice
Chiusolo, Patrizia; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-182831. 2023
Comparing Older Matched Related to Younger Matched Unrelated Donors in Acute Myeloid Leukemia in Remission Using Post-Transplant Cyclophosphamide
Piemontese, Simona; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-182923. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan.
Watanabe, Mizuki; (...); Gluckman, Eliane
Article. 10.1182/bloodadvances.2023010598. 2024
CORD BLOOD TRANSPLANTATION FOR AML: COMPARABLE LFS IN PATIENTS WITH DE NOVO VERSUS SECONDARY AML
Baron, Frederic; (...); Ciceri, Fabio
Meeting Abstract. 2023
Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
Baron, Frederic; (...); Ciceri, Fabio
Article. 10.1111/bjh.19130. 2023
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Mussetti, Alberto; (...); Sureda, Anna
Correction. 10.1038/s41409-023-01967-9. 2023
Cytomegalovirus DNAemia in hematological patients undergoing CD19-directed CAR-T cell therapy: should it be systematically monitored?
Solano de la Asuncion, Carlos; (...); Navarro, David
Letter. 10.1016/j.cmi.2023.05.010. 2023
Cytomegalovirus-driven early-onset lymphocytosis in hematopoietic allogeneic transplant mimicking a T-cell lymphoma progression.
Eiris, Juan, Aguilar, Cristobal, Guerreiro, Manuel
Article. 10.1111/tid.14170. 2023
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
Disseminated toxoplasma infection after hematopoietic stem cell transplantation with myositis and encephalitis.
Asensi Cantó P; (...); Guerreiro M
Article. 10.1111/tid.14067. 2023
EASIX AS A PREDICTOR INDEX FOR NEUROLOGICAL COMPLICATIONS AFTER ANTI-CD19 CAR-T CELL THERAPY IN AGGRESSIVE B-CELL LYMPHOMAS: A STUDY FROM THE GETHTC GROUP
Pena Domingo, Marta; (...); Sureda, Anna
Meeting Abstract. 2023
Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma
Iacoboni, Gloria; (...); Morschhauser, Franck
Meeting Abstract. 10.1182/blood-2023-185035. 2023
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Sanz, Jaime; (...); Ciceri, Fabio
Article. 10.1038/s41409-023-02075-4. 2023
EXTRACORPOREAL PHOTOPHERESIS IN GRAFT-VERSUS-HOST DISEASE.
Canto, Pedro Asensi; (...); Segui, Ines Gomez
Article. 10.1016/j.jtct.2023.07.001. 2023
Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir.
Gimenez, Estela; (...); Navarro, David
Article. 10.1111/tid.14021. 2023
Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Espanol De Trasplante y Terapia Celular (GETH-TC) Study
Fabbri, Nicole; (...); Mussetti, Alberto
Meeting Abstract. 10.1182/blood-2023-185721. 2023
Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)
Laura Fox, Maria; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2022-167747. 2022
High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations.
Chumbita, Mariana; (...); Garcia-Vidal, Carolina
Article. 10.1128/spectrum.00674-23. 2023
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
IMPACT OF BUSULFAN, ETOPOSIDE AND HIGH-DOSE ARA-C (BEA) CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN AML
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 2023
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1111/bjh.18765. 2023
Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Torrent, Anna; (...); Barba, Pere
Meeting Abstract. 10.1182/blood-2023-186388. 2023
IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Marco-Ayala, Javier; (...); Solves, Pilar
Article. 10.1016/j.jtct.2023.01.009. 2023
Impact of SCHOLAR-1 criteria on CAR-T cell therapy efficacy in aggressive B lymphoma. A real-world GELTAMO/GETH study.
Oreiro MB; (...); García-Sancho AM
Article. 10.1016/j.jtct.2023.08.026. 2023
Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
Bastos-Oreiro, Mariana; (...); Martin Garcia-Sancho, Alejandro
Meeting Abstract. 10.1182/blood-2022-166329. 2022
Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil
de la Rubia, Javier; (...); Sanz, Miguel
Meeting Abstract. 2023
Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309
Im, Annie; (...); Pavletic, Steven Z.
Meeting Abstract. 10.1182/blood-2022-169605. 2022
Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02012-5. 2023
Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2022-156231. 2022
Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT
Baron, Frederic; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-186293. 2023
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Lin, Chenyu; (...); Horwitz, Mitchell E.
Article. 10.1016/j.jtct.2023.01.031. 2023
MULTINATIONAL STUDY ASSESSING TREATMENT PATTERNS, OUTCOMES, AND HEALTHCARE RESOURCE UTILIZATION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH REFRACTORY/RESISTANT CYTOMEGALOVIRUS INFECTION, OR INTOLERANCE TO ANTI-CYTOMEGALOVIRUS THERAPIES
Papanicolaou, Genovefa; (...); Hirji, Ishan
Meeting Abstract. 2023
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
Balaguer Rosello, Aitana; (...); Sanz, Jaime
Meeting Abstract. 2023
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.
Nagler, Arnon; (...); Mohty, Mohamad
Article. 10.1186/s13045-023-01450-4. 2023
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT (16, 58, 2023)
Nagler, Arnon; (...); Mohty, Mohamad
Correction. 10.1186/s13045-023-01501-w. 2023
Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study
Roddie, Claire; (...); Jabbour, Elias
Meeting Abstract. 10.1182/blood-2023-179454. 2023
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Cabrero M; (...); Caballero D
Article. 10.1038/s41409-023-02171-5. 2024
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy.
Pinana, Jose Luis; (...); Solano, Carlos
Article. 10.3389/fonc.2024.1389345. 2024
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients.
Piñana JL; (...); Martino R
Article. 10.1038/s41408-022-00778-3. 2023
Outcome of Allogeneic Stem Cell Transplantation in FLT3-TKD-Mutated AML - a Study on Behalf of the Acute Leukemia Working Party of the EBMT
Heinicke, Thomas; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-174233. 2023
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
Socie, Gerard; (...); Mohty, Mohamad
Article. 10.1038/s41409-023-02127-9. 2024
Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo
Bailen, Rebeca; (...); Barba, Pere
Meeting Abstract. 10.1182/blood-2023-185858. 2023
OUTCOMES OF CAR-T CELL THERAPY FOR LARGE B CELL LYMPHOMA IN PATIENTS OF 70 YEARS AND OLDER: MULTICENTRIC REAL WORLD EXPERIENCE
Bailen, Rebeca; (...); Barba, Pere
Meeting Abstract. 2023
Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT.
Baron F; (...); Mohty M
Article. 10.1038/s41409-023-02000-9. 2023
Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.
Rafii, Hanadi; (...); Gluckman, Eliane
Article. 10.1182/bloodadvances.2022007941. 2022
POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) VERSUS ANTI-THYMOCYTE GLOBULIN (ATG) VERSUS COMBINATION FOR GRAFT-VERSUS-HOST DISEASE PREVENTION IN HAPLOIDENTICAL TRANSPLANTATION FOR ADULT ACUTE MYELOID LEUKEMIA: A REPORT FROM THE EBMT
Bazarbachi, Abdul-Hamid; (...); Mohty, Mohamad
Meeting Abstract. 2023
Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT.
Wieczorek, Michele; (...); Mohty, Mohamad
Letter. 10.1002/ajh.26782. 2022
Post-transplant cyclophosphamide separates graft-versus host disease (GVHD) and graft versus leukemia (gvl) effects after HLA- matched stem-cell transplantation (sct) for AML
Shimoni, A.; (...); Mohty, M.
Meeting Abstract. 2022
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel, Sebastian; (...); Mohty, Mohamad
Article. 10.1002/cncr.35004. 2023
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with all treated in CR1 with allo-HCT from matched unrelated donors. A study from ALWP of the EBMT
Giebel, S.; (...); Mohty, M.
Meeting Abstract. 2022
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in HLAMatched and Haploidentical Donor Transplants for Patients with Hodgkin disease: A Comparative Study of the LWP EBMT
Montoro, Juan; (...); Glass, Bertram
Meeting Abstract. 10.1182/blood-2023-179829. 2023
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Montoro, Juan; (...); Glass, Bertram
Article. 10.1016/j.jtct.2023.11.021. 2024
Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party
Abou Dalle, Iman; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-187095. 2023
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party
Bazarbachi, Ali; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-182823. 2023
Rationale for combined therapies in severe-to-critical COVID-19 patients
Gonzaga, Aitor; (...); Soria, Bernat
Review. 10.3389/fimmu.2023.1232472. 2023
Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.
Asensi Cantó P; (...); Gómez-Seguí I
Article. 10.1016/j.jtct.2023.09.001. 2023
Recent advances in allogeneic transplantation for acute myeloid leukemia.
Montoro J, Balaguer-Roselló A, Sanz J
Article. 10.1097/CCO.0000000000000992. 2023
Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.07.008. 2023
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
Pinana, Jose Luis; (...); Solano, Carlos
Article. 10.3390/v15102066. 2023
Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances.
Piñana JL; (...); Navarro D
Article. 10.1111/tid.14117. 2023
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Mussetti, Alberto; (...); Sureda, Anna
Article. 10.1038/s41409-023-01949-x. 2023
Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era
Mussetti, Alberto; (...); Sureda, Anna
Meeting Abstract. 10.1182/blood-2022-160000. 2022
Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study
Escamilla Gomez, Virginia; (...); Perez-Simon, Jose A.
Meeting Abstract. 10.1182/blood-2022-164561. 2022
Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.
Roddie, Claire; (...); Jabbour, Elias
Meeting Abstract. 2023
Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy
Iacoboni, Gloria; (...); Abrisqueta, Pau
Meeting Abstract. 10.1182/blood-2022-169219. 2022
SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients: What Do We Know, and What Remains to Be Determined?
Pinana, Jose Luis, Guerreiro, Manuel, Solano, Carlos
Review. 10.3390/hemato4020014. 2023
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
Pinana, Jose Luis; (...); Solano, Carlos
Article. 10.1038/s41409-023-01946-0. 2023
Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using PostTransplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
Sanz, Jaime; (...); Ciceri, Fabio
Meeting Abstract. 10.1182/blood-2023-180075. 2023
SECOND ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT2) FOR PRIMARY GRAFT FAILURE IN PATIENTS WITH ACUTE LEUKEMIA IN REMISSION: ON BEHALF OF THE ALWP OF THE EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2023
Secondary neoplasms after umbilical cord blood transplantation. On behalf of eurocord and the european group for blood and marrow transplantation
El Ayoubi, H. Rafii; (...); Gluckman, E.
Meeting Abstract. 2022
Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT.
Kharfan-Dabaja, Mohamed A.; (...); Mohty, Mohamad
Article. 10.1097/HS9.0000000000000920. 2023
Starkeya nomas sp. nov., a prosthecate and budding bacterium isolated from an immunocompromized patient.
Sahuquillo-Arce JM; (...); López-Hontangas JL
Article. 10.1099/ijsem.0.005805. 2023
T REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH SECONDARY VERSUS DE NOVO AML: A STUDY FROM THE ALWP /EBMT
Nagler, Arnon; (...); Mohty, Mohamad
Meeting Abstract. 2023
TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT
Swoboda, R.; (...); Mohty, M.
Meeting Abstract. 2022
T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.01.016. 2023
The Impact of DNMT3A Mutation on Survival of AML Patients Receiving Allogeneic Hematopoietic Cell Transplantation in First Remission Depends on the Karyotype and CoOccurring Mutations: On Behalf of the EBMT Acute Leukemia Working Party
Dalle, Abou; (...); Mohty, Mohamad
Meeting Abstract. 10.1182/blood-2023-179531. 2023
The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy
Lacoboni, Gloria; (...); Abrisqueta Costa, Pau
Meeting Abstract. 10.1182/blood-2023-184942. 2023
Thiotepa-based reduced-intensity conditioning are a valid alternative to total-body irradiation-based regimens in patients with acute lymphoblastic leukemia: A study of the alwp of the ebmt
Battipaglia, G.; (...); Mohty, M.
Meeting Abstract. 2022
Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Battipaglia, Giorgia; (...); Mohty, Mohamad
Article. 10.1016/j.jtct.2023.09.028. 2024
Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy
Benzaquen, Ana; (...); Solano, Carlos
Article. 10.1038/s41409-023-02114-0. 2024
TORQUE TENO VIRUS PLASMA DNA LOAD: A NOVEL PROGNOSTIC BIOMARKER IN CAR-T THERAPY
Hernani, Rafael; (...); Solano, Carlos
Meeting Abstract. 2023
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.
Solves, Pilar; (...); Sanz, Jaime
Article. 10.3390/jcm12103467. 2023
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
Al Hamed, Rama; (...); Mohty, Mohamad
Article. 10.1002/cncr.34843. 2023
Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation.
Piñana JL; (...); de la Camara, Rafael
Article. 10.1093/infdis/jiad268. 2024
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023